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Introduction 
The “art of medicine” becomes relevant in 
dermatologic practice when balancing the desires of 
the patient with standards of clinical practice. To 
illustrate this situation and discuss the legal and 
ethical dilemmas involved, we present the following 
hypothetical case scenario. 
Case Scenario 
Dr. Benjamin Cat is a dermatologist seeing a 
cosmetically-sensitive 65-year-old woman for the 
first time. The patient, presents with an ulcerative 
lesion on her nose. After Dr. Cat expresses his 
concern and explains the risks and benefits of a 
shave biopsy, the patient reluctantly agrees to this 
next step in management. Histopathology confirms 
the diagnosis of infiltrative basal cell carcinoma 
(BCC), positive at the deep margins. Dr. Cat reviews 
this diagnosis with the patient during a follow-up 
visit and recommends Mohs surgery. The patient 
adamantly refuses Mohs surgery, as she is terrified of 
the potential residual scar. Rather, she is only 
interested in topical treatment with imiquimod, 
which she heard about from her friend who received 
this treatment for her BCC. Dr. Cat explains that 
although imiquimod is an approved treatment for 
non-facial superficial BCC with a maximum two-
centimeter diameter, which may have been her 
friend’s diagnosis, it is neither approved for 
infiltrative BCC nor for facial lesions. Despite this 
explanation, the patient refuses treatment with 
Mohs surgery and insists upon therapy with 
imiquimod. 
Treatment Options 
There are several different approaches that the 
dermatologist can take when considering the 
treatment of infiltrative BCC for this patient. One 
option is to do as the patient requests and prescribe 
treatment with topical imiquimod 5% cream 5-
times-a-week for 6-12 weeks with follow-up 
performed every three weeks. If choosing this first 
option, the dermatologist would also document that 
the patient received full informed consent, being 
sure to include a discussion of the off-label use of the 
drug, lower cure rate when compared to Mohs 
surgery, and possibility that the cancer may 
subsequently spread locally and/or even 
Abstract 
In medical practice, physicians are sometimes faced 
with patients who reject the gold-standard 
treatment for a condition. In this hypothetical clinical 
scenario, we present the case of a patient who refuses 
Mohs micrographic surgery for management of 
infiltrative basal cell carcinoma and instead requests 
off-label therapy with imiquimod. We discuss the 
treating dermatologist’s options in response to this 
patient’s request and the ethical considerations 
surrounding the case. We conclude that the 
physician has the right to refuse to provide treatment 
that deviates from standard clinical practice but that 
the physician should counsel the patient on all 
options, provide thorough informed consent, offer 
contact information for the patient to pursue a 
second opinion or a radiation oncology referral, and 
ensure safe transfer of care should the patient desire 
treatment with a different provider. 
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metastasize. Alternatively, the dermatologist could 
refuse to prescribe topical treatment, as it is not a 
reasonable option given the BCC subtype. Another 
option is to offer to refer her to another 
dermatologist/Mohs surgeon for a second opinion or 
refer her for a radiation therapy consultation. 
 
Discussion 
When contemplating the above treatment options, 
the primary ethical dilemma that is encountered is 
the conflict between autonomy and beneficence, 
occurring in the context of a legal climate that 
pressures physicians to practice defensive medicine. 
Based on the principle of autonomy, the patient has 
the right to make her own decision with a full 
understanding of the information pertinent to her 
case and without external controlling forces. She 
must therefore be given proper informed consent, 
including a discussion of all of her treatment options, 
including the risks and benefits associated with each 
option. However, although the patient has the right 
to make her own decision, the physician is also 
bound by his or her own code of ethics to provide 
beneficent care by acting in the best interest of the 
patient. 
Mohs surgery is the treatment of choice for BCCs in 
cosmetically-sensitive areas owing to its high cure 
rate and tissue-preserving technique. Radiation is a 
reasonable alternative for primary treatment of BCCs 
in patients who are not surgical candidates or who 
wish to avoid surgical treatment, though there are 
potential adverse effects including poor long-term 
cosmetic results. As noted above, topical treatment 
with imiquimod 5% cream is currently FDA approved 
for treatment of small non-facial superficial BCCs, but 
not infiltrative BCCs at any body site. Vismodegib is 
indicated for metastatic or locally advanced BCCs in 
patients with recurrence after surgery or in those 
who are not candidates for surgery or radiation [1]. 
Mohs surgery is currently the most effective 
treatment for BCC with a recurrence rate of 1% at 5-
year follow-up, whereas the recurrence rate after 
radiation treatment is 8.7% [1]. There is currently 
limited data on the efficacy of imiquimod 5% cream 
for infiltrative BCCs, though one case series reported 
a 35% recurrence rate in all cases, with a 40% 
recurrence rate for infiltrative BCCs [2]. 
When considering the above treatments for BCC, 
Mohs surgery is the most effective option and is 
indicated in this patient’s case. The physician is thus 
ethically motivated by the principle of beneficence 
to provide the patient with Mohs surgery. The 
physician should elucidate the root cause of the 
patient’s anxiety over cosmetic outcomes and 
counsel and educate the patient on outcomes after 
Mohs surgery using pre- and postoperative 
photographs of prior patients when appropriate. 
The administration of imiquimod 5% cream in this 
case would be an off-label use. Off-label use of 
medications is common practice in dermatology and 
does not, by itself, qualify as either medical 
malpractice or physician negligence. However, a 
physician may be found negligent if harm was done 
to the patient after the physician deviated from the 
standard of care by prescribing an off-label 
medication [3]. Although informed consent is not 
legally necessary when prescribing medications off-
label, it may be advisable in certain cases [3]. There is 
limited evidence at this time demonstrating the 
efficacy of imiquimod 5% cream for treating 
infiltrative BCCs [2], and its use is currently only 
recommended as monotherapy for superficial BCCs 
[4]. Thus, the dermatologist in this case might be at 
risk for legal ramifications if he/she prescribes 
imiquimod for this patient, especially if the 
treatment is not efficacious and her BCC 
subsequently recurs, enlarges, or metastasizes.  
Recommended Approach 
The legally safest option would be to refuse to 
prescribe topical therapy and offer referrals to 
another dermatologist/Mohs surgeon for a second 
opinion or refer her for a radiation therapy 
consultation. The dermatologist should provide the 
patient with extensive counseling on the risks and 
benefits of each treatment and ask the patient to 
sign an informed consent expressing her 
understanding of her treatment options and her 
choice to refuse Mohs surgery. Although the patient 
may not get the treatment she wants, she is given the 
option to thoroughly discuss her diagnosis and 
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management with another doctor and to explore 
alternative therapeutic options. 
When a physician is faced with a patient refusing the 
standard of care, the physician can draft a document 
stating the patient’s disease and the treatments that 
are within the standard of care. Should the patient 
refuse these treatment options, the patient, 
physician, and a witness should sign this document 
including initialing next to each treatment option 
that the patient has refused. This form should be 
retained in the patient’s medical record. If the patient 
refuses to sign the document, the refusal should be 
witnessed by someone in the office and noted in the 
medical record. It would be wise at this time to 
inform the malpractice carrier that this patient may 
make a claim against the physician. Should the 
patient report the refusal of care to the state medical 
board, the physician should contact a lawyer. 
Additionally, if the patient does not choose definitive 
treatment with Mohs surgery, the current physician 
should offer the patient a second opinion from a 
similarly qualified dermatologist as well as a 
consultation for radiation therapy. Should the 
patient agree to one or both options, the physician 
should give the patient contact information for the 
appropriate alternative practitioners. The referring 
doctor should contact these other providers to 
inform them of the background information of the 
case. If the patient chooses a treatment offered by a 
different physician, the current provider should 
document that the patient has transferred her care 
elsewhere. 
Potential adverse consequences of each option 
Although prescribing imiquimod after obtaining 
informed consent is the option that most respects 
the patient’s autonomy, it puts the provider at risk by 
deviating from standard clinical practice. This option 
may be viable if there is a very thorough discussion 
during the informed consent, if the patient agrees to 
re-biopsy later on, and if the patient would consider 
treatment with Mohs surgery if the cancer does not 
respond to topical therapy. Refusing to prescribe 
topical treatment may be harmful to the therapeutic 
alliance and puts the patient at risk of obtaining no 
treatment. However, it is within the physician’s rights 
to refuse to provide treatment that does not follow 
standard of care. Providing referrals to other 
physicians is also an acceptable response, but 
referring the patient to others runs the risk of 
“kicking the can down the road.” The current treating 
physician cannot be certain of whether the patient 
would pursue further care and does not know what 
treatment the subsequent provider would 
recommend. 
 
Conclusion 
Although the patient has the right to reject the gold-
standard treatment for her condition, the physician, 
too, has the right to refuse to provide treatment that 
deviates from standard clinical practice. The 
physician should counsel the patient on all of her 
treatment options, obtain thorough informed 
consent for whatever option is chosen, offer contact 
information for a second opinion or referral to a 
radiation oncologist if the patient wishes, and ensure 
a safe transfer of care should the patient choose to 
continue care with a different provider.  
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